29.49
Kymera Therapeutics Inc Borsa (KYMR) Ultime notizie
Stifel Nicolaus Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR) - Defense World
Deutsche Bank AG Has $2.91 Million Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera Therapeutics (KYMR) Receives 'Buy' Rating from Stifel with $55 Price Target | KYMR Stock News - GuruFocus
Kymera Therapeutics (KYMR) Gains Buy Rating from Stifel with Promising Outlook | KYMR Stock News - GuruFocus
Kymera’s KT-621 shows promise in preclinical asthma study - Investing.com Australia
Kymera Therapeutics (KYMR) Showcases Promising Preclinical Data - GuruFocus
Kymera Therapeutics Presents New Preclinical Data for KT-621, a - GuruFocus
Kymera’s KT-621 shows promise in preclinical asthma study By Investing.com - Investing.com India
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference - The Manila Times
Kymera Therapeutics presents preclinical data for KT-621 - TipRanks
Breakthrough: New Oral Asthma Drug Shows Superior Results to Dupilumab in Latest Clinical Data - Stock Titan
Transcript : Kymera Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 03 - marketscreener.com
Kymera at BofA Conference: Strategic FDA and Manufacturing Insights By Investing.com - Investing.com Nigeria
Kymera at BofA Conference: Strategic FDA and Manufacturing Insights - Investing.com
Kymera TherapeuticsIntriguing Degradation Thesis, But A Bit Powder Puff (NASDAQ:KYMR) - Seeking Alpha
Kymera Therapeutics (KYMR) Target Price Adjusted by UBS | KYMR S - GuruFocus
UBS Adjusts Price Target on Kymera Therapeutics to $70 From $72, Maintains Buy Rating - marketscreener.com
Kymera Therapeutics (KYMR) Target Price Revised by UBS | KYMR St - GuruFocus
Analysts Are Betting On Kymera Therapeutics, Inc. (NASDAQ:KYMR) With A Big Upgrade This Week - simplywall.st
When the Price of (KYMR) Talks, People Listen - news.stocktradersdaily.com
The Analyst Verdict: Kymera Therapeutics In The Eyes Of 4 Experts - Benzinga
Kymera Therapeutics (KYMR) Receives Reaffirmed 'Buy' Rating from - GuruFocus
Kymera Therapeutics (KYMR) Stock Rating Maintained, Price Target - GuruFocus
Kymera Therapeutics (KYMR) Faces Price Target Reduction Amid Str - GuruFocus
Truist maintains Kymera Therapeutics stock buy rating and $35 target By Investing.com - Investing.com UK
Kymera unveils new oral IRF5 degrader for immuno-inflammatory diseases - BioWorld MedTech
B. Riley Adjusts Kymera Therapeutics Price Target to $38 From $41, Maintains Neutral Rating - marketscreener.com
BofA Adjusts Price Target for Kymera Therapeutics (KYMR) | KYMR Stock News - GuruFocus
Kymera Therapeutics: Promising Pipeline and Strategic Decisions Justify Buy Rating - TipRanks
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2025 Earnings Call Transcript - Insider Monkey
Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Kymera advances oral drug for autoimmune diseases - Investing.com
Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Up on Strong Earnings - Defense World
Decoding Kymera Therapeutics Inc (KYMR): A Strategic SWOT Insigh - GuruFocus
Kymera advances oral drug for autoimmune diseases By Investing.com - Investing.com India
Earnings call transcript: Kymera Therapeutics beats EPS forecast in Q1 2025 - Investing.com
Kymera (KYMR) Financial Update: Strong Cash Position Supports Future Developments | KYMR Stock News - GuruFocus
Kymera Therapeutics Reports Strong Pipeline Progress - TipRanks
Kymera Therapeutics (KYMR) Launches Innovative Oral Immunology P - GuruFocus
Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings: Revenue Soars t - GuruFocus
Kymera Therapeutics Announces First Quarter 2025 Financial Resul - GuruFocus
Kymera Therapeutics (KYMR) Surpasses Revenue Estimates with Stro - GuruFocus
Kymera Therapeutics Expands Industry Leading Immunology Pipeline - GuruFocus
Kymera Therapeutics’ Earnings Call: Resilience and Strategic Growth - TipRanks
Earnings call transcript: Kymera Therapeutics beats EPS forecast in Q1 2025 By Investing.com - Investing.com South Africa
Truist maintains Buy on Kymera stock, reiterates $53 target By Investing.com - Investing.com Canada
Kymera Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging - Zacks Investment Research
Kymera (KYMR) Financial Update: Strong Cash Position Supports Fu - GuruFocus
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Kymera Therapeutics Q1 Loss Widens, Collaboration Revenue Rises - marketscreener.com
Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings: Revenue Soars to $22.1M, Beating Estimates; Net Loss Widens - GuruFocus
Kymera Therapeutics (KYMR) Surpasses Revenue Estimates with Strong Q1 Performance | KYMR Stock News - GuruFocus
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):